Coronavirus
AstraZeneca and Johnson & Johnson Research Vaccine Modifications in Response to Blood Clot Reports
Johnson & Johnson and AstraZeneca are conducting early stage research into whether potential modifications of their Covid-19 vaccines could reduce or eliminate the risk of rare, but serious, blood clots associated with the shots.
The blood clotting issue, which some scientists are calling vaccine-induced immune thrombotic thrombocytopenia, or VITT, has been linked to both shots. Scientists have been discovering clues into how the clots form, boosting hopes of possibly reengineering the shots, a person familiar with the matter told CNBC.
The Wall Street Journal reported the news earlier Tuesday.
In a statement to CNBC, J&J said it supports “continued research and analysis as we work with medical experts and global health authorities.”
